Black Diamond Therapeutics (BDTX) Times Interest Earned (2020)
Black Diamond Therapeutics' (BDTX) quarterly Times Interest Earned came in at 15028.0 in Q2 2020.
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) Times Interest Earned (2020) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported Times Interest Earned for 1 consecutive years, with 15028.0 the latest figure, recorded in Q2 2020.
- For the quarter ending Q2 2020, Times Interest Earned changed N/A year-over-year to 15028.0; the trailing twelve-month figure through Sep 2021 stood at 123975.0 (down 118.53% YoY), and the FY2020 full-year result was 69570.0, changed N/A from the prior year.
- Times Interest Earned was little changed at 15028.0 in Q2 2020 per BDTX's latest filing.
- Across five years, Times Interest Earned topped out at 15028.0 in Q2 2020 and bottomed at 15028.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - | - |